Mycoplasma hyopneumoniae bacterin vaccine
View Patent ↗The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.
1. A vaccine composition for immunizing a porcine animal against infection by Mycoplasma pneumoniae which comprises
an immunizing amount of Mycoplasma pneumoniae bacterin;
an adjuvant mixture comprising an acrylic acid polymer and a mixture of a metabolizable oil and a polyoxyethylene-polyoxypropylene block copolymer; and
a pharmaceutically acceptable carrier, wherein said vaccine composition, after a single dose administration, elicits protective immunity lasting for six months in said porcine animal against said Mycoplasma pneumoniae infection.
2. The vaccine composition of claim 1 wherein the adjuvant mixture comprises about 1-25% v/v of the vaccine composition.
3. The vaccine composition of claim 1 , wherein the metabolizable oil is squalane or squalene.
4. The vaccine composition of claim 3 , wherein the acrylic acid polymer is a polymer of acrylic acid cross-linked with polyallylsucrose having the chemical formula (CH 2 CHOOOH) n .
5. The vaccine composition as in any of claims 1 , 2 , 3 or 4 , further comprising at least one bacterin selected from the group consisting of Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis and leptospira.